Caroline Behler

634 total citations
16 papers, 406 citations indexed

About

Caroline Behler is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Caroline Behler has authored 16 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Hematology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Caroline Behler's work include Lymphoma Diagnosis and Treatment (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). Caroline Behler is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). Caroline Behler collaborates with scholars based in United States, Germany and Argentina. Caroline Behler's co-authors include Neil C. Josephson, Ahmed Sawas, Ann S. LaCasce, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas‐Ohlmayer, Julie M. Vose, Jeffrey Matous, Eric Cheung and Ranjana H. Advani and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Caroline Behler

15 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Caroline Behler United States 9 295 198 186 129 44 16 406
Fred Rosenfelt United States 8 341 1.2× 209 1.1× 188 1.0× 195 1.5× 88 2.0× 15 514
Pamela B. Allen United States 11 303 1.0× 99 0.5× 229 1.2× 74 0.6× 61 1.4× 56 461
David Straus United States 6 467 1.6× 93 0.5× 280 1.5× 154 1.2× 123 2.8× 8 536
Andrés López Spain 8 382 1.3× 87 0.4× 302 1.6× 97 0.8× 30 0.7× 16 498
Antonella Ferrari Italy 10 187 0.6× 114 0.6× 100 0.5× 114 0.9× 30 0.7× 18 356
M F D'Agay France 7 253 0.9× 83 0.4× 151 0.8× 136 1.1× 38 0.9× 8 380
Gene Resnick United States 5 255 0.9× 84 0.4× 165 0.9× 78 0.6× 77 1.8× 6 348
Mohammed Al‐Hamadani United States 5 178 0.6× 49 0.2× 170 0.9× 77 0.6× 24 0.5× 10 302
Katharine L. Lewis Australia 12 213 0.7× 59 0.3× 103 0.6× 187 1.4× 111 2.5× 47 456
Nelofar Shafi United States 10 149 0.5× 35 0.2× 157 0.8× 54 0.4× 31 0.7× 16 311

Countries citing papers authored by Caroline Behler

Since Specialization
Citations

This map shows the geographic impact of Caroline Behler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline Behler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline Behler more than expected).

Fields of papers citing papers by Caroline Behler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline Behler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline Behler. The network helps show where Caroline Behler may publish in the future.

Co-authorship network of co-authors of Caroline Behler

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline Behler. A scholar is included among the top collaborators of Caroline Behler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline Behler. Caroline Behler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
LaCasce, Ann S., R. Gregory Bociek, Ahmed Sawas, et al.. (2018). Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 132(1). 40–48. 152 indexed citations
2.
LaCasce, Ann S., Gregory Bociek, Ahmed Sawas, et al.. (2015). Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood. 126(23). 3982–3982. 43 indexed citations
3.
Girnius, Saulius, Suman Kambhampati, Michal G. Rose, et al.. (2015). A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. British Journal of Haematology. 169(1). 36–43. 8 indexed citations
4.
Hung, Annie, et al.. (2015). Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation. SHILAP Revista de lepidopterología. 2015. 1–5. 3 indexed citations
5.
LaCasce, Ann S., R. Gregory Bociek, Jeffrey Matous, et al.. (2014). Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy. Blood. 124(21). 293–293. 20 indexed citations
6.
Wieduwilt, Matthew J., Francisco Valles, Samar Issa, et al.. (2012). Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI. Clinical Cancer Research. 18(4). 1146–1155. 99 indexed citations
7.
8.
9.
10.
Allen, Eliezer M. Van, et al.. (2011). Off-Label Use of Rituximab in a Multipayer Insurance System. Journal of Oncology Practice. 7(2). 76–79. 18 indexed citations
11.
12.
Behler, Caroline, Norah A. Terrault, Joan Etzell, & Lloyd E. Damon. (2009). Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. Journal of Medical Case Reports. 3(1). 7335–7335. 9 indexed citations
13.
Behler, Caroline, Eric Vittinghoff, Feng Lin, et al.. (2007). Hematologic Toxicity Associated with Interferon-Based Hepatitis C Therapy in HIV Type 1-Coinfected Subjects. Clinical Infectious Diseases. 44(10). 1375–1383. 13 indexed citations
14.
Behler, Caroline & Lawrence D. Kaplan. (2006). Advances in the management of HIV-related non-Hodgkin lymphoma. Current Opinion in Oncology. 18(5). 437–443. 13 indexed citations
15.
Behler, Caroline, et al.. (2005). Anemia and HIV in the Antiretroviral Era: Potential Significance of Testosterone. AIDS Research and Human Retroviruses. 21(3). 200–206. 20 indexed citations
16.
Brandenburg, Vincent, Markus Ketteler, Rolf Dario Frank, et al.. (2002). Bone pain with scintigraphy suggestive of widespread metastases—do not forget phosphate. Nephrology Dialysis Transplantation. 17(3). 504–507. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fred Rosenfelt Breakdown of academic impact, for papers by Pamela B. Allen Breakdown of academic impact, for papers by David Straus Breakdown of academic impact, for papers by Andrés López Breakdown of academic impact, for papers by Antonella Ferrari Breakdown of academic impact, for papers by M F D'Agay Breakdown of academic impact, for papers by Gene Resnick Breakdown of academic impact, for papers by Mohammed Al‐Hamadani Breakdown of academic impact, for papers by Katharine L. Lewis Breakdown of academic impact, for papers by Nelofar Shafi
Rankless by CCL
2026